Alumni out a few decades may remember Kendall Square as an undistinguished place. No longer. Kendall Square has become an international model for how to seed a neighborhood with great ideas, thanks to MIT’s management of its commercial real estate portfolio. Kendall Square today is a nexus for biotech and pharma companies plus hordes of startups. And, drawn to MIT, more are coming.
As part of MIT’s 2030 planning process, MIT is proposing to enliven the streetscape with restaurants and landscape improvements as well as building spaces for residences, research facilities, and starts ups.
In recent presentations to the Cambridge Planning Board, MIT has described plans to redevelop Institute property in the East Campus/Kendall Square area, which would include a more inviting eastern gateway to the campus. You can download the presentation and learn more in Cambridge Planning Board cites satisfaction with Kendall proposal.
The January-February MIT Faculty Newsletter is weighing in on the plans, particularly with concerns about faculty consultation and the balance of commercial development vs. space for research facilities and graduate student housing.
Meanwhile, things in the square are hopping. Just ask Michael Gilman ′76, a life sciences entrepreneur whose undergrad lab was within sight of Kendall Square. His start-up, Stromedix, had offices a 15-minute walk out of the square, until it was acquired by Biogen Idec in 2012. Now he works a block north of Kendall Square overseeing several drug development programs for Biogen. Sunday’s Boston Globe Innovation Economy blog post describes him and the 2.5 million square feet of new offices and lab space proposed for the area.
For more on campus development, check out the Slice of MIT post, “What’s Going Up at MIT?”